Change from baseline in HbA1c at Week 40
*P<0.0001
REDUCTIONS
VS TRULICITY®
–1.1%
–1.5%*
–1.4%
–1.8%*
Trulicity®
0.75 mg
n=299
Ozempic®
0.5 mg
n=301
Trulicity®
1.5 mg
n=299
Ozempic®
1 mg
n=300
Mean baseline: 8.2%
VS JANUVIA®
VS INVOKANA®
ADA/EASD REPORT
Ozempic® got more patients to target across all head-to-head trials1,2,28,30*
UP TO
ACHIEVED ADA TARGET OF HbA1c
VS OTHER DIABETES TREATMENTS1,2,9,28,30*
- ADA=American Diabetes Association.
- *Other diabetes treatments refer to Januvia®, Trulicity®, Bydureon®, Invokana®, Victoza® and Lantus®.
Ozempic® demonstrated superior HbA1c reductions in all head-to-head trials1,2,28
Change from baseline* in HbA1c (%)1,2,28
†P<0.0001 for all trials
SUSTAIN 7 vs Trulicity®
SUSTAIN 4 vs Lantus®
SUSTAIN 2 vs Januvia®
SUSTAIN 8 vs Invokana®
Mean baseline: 8.2%
Mean baseline: 8.1%
Mean baseline: 8.1%
Mean baseline: 8.3%
– 1.4
– 1.8†
– 0.8
– 1.6†
– 0.5
– 1.6†
– 1.0
– 1.5†
Trulicity® 1.5 mg (n=299)
Ozempic® 1 mg (n=300)
Lantus® 29.2 IU‡ (n=360)
Ozempic® 1 mg (n=360)
Januvia® 100 mg (n=407)
Ozempic® 1 mg (n=409)
Invokana® 300 mg (n=394)
Ozempic® 1 mg (n=394)
CONSISTENTLY SUPERIOR HbA1c REDUCTIONS
vs other diabetes treatments1,2,28§
x 
Ozempic® demonstrated superior weight loss vs Januvia® sustained over 1 year1
Change from baseline in weight at Week 561
*P<0.0001
– 1.9 kg
– 4.3 kg*
– 6.1 kg*
- Januvia®
- 100 mg
- n=407
- Ozempic®
- 0.5 mg
- n=409
- Ozempic®
- 1 mg
- n=409
Mean baseline: 89.5 kg
vs januvia®1†
†Results apply to 1-mg dose of Ozempic® vs Januvia® 100 mg.1
Ozempic® demonstrated superior HbA1c reductions vs Januvia®
Change from baseline in HbA1c at Week 561
*P<0.0001
–0.5%
–1.3%*
–1.6%*
- Januvia®
- 100 mg
- n=407
- Ozempic®
- 0.5 mg
- n=409
- Ozempic®
- 1 mg
- n=409
Mean baseline: 8.1%
HbA1c REDUCTIONS
vs januvia®1†
†Results apply to 1-mg dose of Ozempic® vs Januvia® 100 mg.1
ABSOLUTE WEIGHT LOSS
ABSOLUTE HbA1c
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .content-wrapper{
position: absolute;
top: 0;
left: 0;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] [id$=popup1PassText]{
position: absolute;
text-align: center;
top: 435px;
width: 281px;
left: 587px;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] #popup1PassText span{
text-align: center;
font-family: 'Frutiger LT Cond';
font-size: 14px;
font-weight: 600;
color: #fff;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] [id$=popup1ActText]{
position: absolute;
text-align: center;
font-size: 10px;
top: 12px;
width: 100%;
left: -4px;
letter-spacing: 0.5px;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] #popup1ActText span{
text-align: center;
font-family: 'Frutiger LT Cond';
font-size: 14px;
font-weight: 600;
color: #fff;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .wrapper-for-text{
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
overflow: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] [id$=popup1ButtonBg]{
width: 260px;
height: 60px;
top: 419px;
left: 585px;
position: absolute;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .wrapper-for-filler{
position: absolute;
top: 423px;
left: 593px;
width: 247px;
height: 35px;
border-radius: 15px;
overflow: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .filler{
position: absolute;
left: 0;
width: 229px;
height: 100%;
border-radius: 15px;
overflow: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .handler{
position: absolute;
left: 794px;
top: 423px;
width: 48px;
height: 51px;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .tabActive .move-left{
transform: translate(-196px ,0);
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .tabActive .move-right{
transform: translate(196px ,0);
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .move-left,
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .move-right{
transition: transform 0.5s linear;
transform: translate(0, 0);
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .content-wrapper [id$=popup1HandlerReverse],
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .content-wrapper.tabActive [id$=popup1Handler]{
visibility: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .content-wrapper [id$=popup1Handler],
#presentationEngine [id$=hbA1cResultsPopup1EHTML] .content-wrapper.tabActive [id$=popup1HandlerReverse]{
visibility: visible;
}
setTimeout(() => {
let clickCallback = function () {
document.querySelector('#presentationEngine [id$=hbA1cResultsPopup1EHTML] .content-wrapper').classList.toggle('tabActive');
};
const toggle1Selector = '#presentationEngine [id$=hbA1cResultsPopup1State1Toggler]';
const toggle2Selector = '#presentationEngine [id$=hbA1cResultsPopup1State2Toggler]';
var targets = [document.querySelector(toggle1Selector), document.querySelector(toggle2Selector)];
targets.forEach((target) => {
target.onclick = clickCallback;
});
}, 1000)
x 
Ozempic® delivered superior weight loss vs Invokana®
Change from baseline in weight at Week 5228
*P=0.0029
– 5.3 kg*
– 4.2 kg*
- Invokana®
- 300 mg
- n=394
- Ozempic®
- 1 mg
- n=394
Mean baseline: 90.2 kg
WEIGHT
LOSS
WITH OZEMPIC® 1 MG
vs INVOKANA®1
Once-weekly Ozempic® delivered superior HbA1c reductions vs Invokana®
Change from baseline in HbA1c at Week 5228
*P<0.0001
– 1.0%*
–1.5%*
- Invokana®
- 300 mg
- n=394
- Ozempic®
- 1 mg
- n=394
Mean baseline: 8.3%
REDUCTIONS
vs INVOKANA®28
ABSOLUTE WEIGHT LOSS
ABSOLUTE HbA1c
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .content-wrapper{
position: absolute;
top: 0;
left: 0;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] [id$=popup2PassText]{
position: absolute;
text-align: center;
top: 435px;
width: 281px;
left: 587px;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] #popup2PassText span{
text-align: center;
font-family: 'Frutiger LT Cond';
font-size: 14px;
font-weight: 600;
color: #fff;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] [id$=popup2ActText]{
position: absolute;
text-align: center;
font-size: 10px;
top: 12px;
width: 100%;
left: -4px;
letter-spacing: 0.5px;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] #popup2ActText span{
text-align: center;
font-family: 'Frutiger LT Cond';
font-size: 14px;
font-weight: 600;
color: #fff;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .wrapper-for-text{
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
overflow: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] [id$=popup2ButtonBg]{
width: 260px;
height: 60px;
top: 419px;
left: 585px;
position: absolute;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .wrapper-for-filler{
position: absolute;
top: 423px;
left: 593px;
width: 247px;
height: 35px;
border-radius: 15px;
overflow: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .filler{
position: absolute;
left: 0;
width: 229px;
height: 100%;
border-radius: 15px;
overflow: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .handler{
position: absolute;
left: 794px;
top: 423px;
width: 48px;
height: 51px;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .tabActive .move-left{
transform: translate(-196px ,0);
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .tabActive .move-right{
transform: translate(196px ,0);
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .move-left,
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .move-right{
transition: transform 0.5s linear;
transform: translate(0, 0);
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .content-wrapper [id$=popup2HandlerReverse],
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .content-wrapper.tabActive [id$=popup2Handler]{
visibility: hidden;
}
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .content-wrapper [id$=popup2Handler],
#presentationEngine [id$=hbA1cResultsPopup2EHTML] .content-wrapper.tabActive [id$=popup2HandlerReverse]{
visibility: visible;
}
setTimeout(() => {
let clickCallback = function(){
document.querySelector('#presentationEngine [id$=hbA1cResultsPopup2EHTML] .content-wrapper').classList.toggle('tabActive');
};
const toggle1Selector = '#presentationEngine [id$=hbA1cResultsPopup2State1Toggler]';
const toggle2Selector = '#presentationEngine [id$=hbA1cResultsPopup2State2Toggler]';
var targets = [document.querySelector(toggle1Selector), document.querySelector(toggle2Selector)];
targets.forEach((target)=>{
target.onclick = clickCallback;
});
}, 1000)
x 2018 ADA/EASD consensus report: Lower blood glucose to reduce long-term
2018 ADA/EASD consensus report: Lower blood glucose to reduce long-term
complications of diabetes6
2018 ADA/EASD CONSENSUS
REPORT RECOGNISES THAT
SEMAGLUTIDE
MAY BE THE GLP-1 RA WITH
THE GREATEST
GLUCOSE-LOWERING EFFECT6
ADA=American Diabetes Association; EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonist.